After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Multiple chemicals in cigarette smoke and e-cigarettes alter the function of a key type of lung immune cell. Cigarette ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.